Edition:
United States

Mayne Pharma Group Ltd (MYX.AX)

MYX.AX on Australia Stock Exchange

1.10AUD
26 May 2017
Change (% chg)

-- (--)
Prev Close
$1.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,004,046
52-wk High
$2.11
52-wk Low
$1.04

Latest Key Developments (Source: Significant Developments)

Mayne Pharma Group appoints Nick Freeman as new group CFO
Wednesday, 8 Mar 2017 05:54pm EST 

Mayne Pharma Group Ltd : Mayne pharma appoints new group cfo and company secretary-myx.ax .Appointed Nick Freeman as group chief financial officer and company secretary.  Full Article

Mithra Pharmaceuticals concludes exclusive license and supply agreement with Mayne Pharma for marketing of Myring in US
Tuesday, 28 Feb 2017 03:07am EST 

Mithra Pharmaceuticals SA : Mithra concludes exclusive license and supply agreement with Mayne Pharma for myring marketing in the United States . Under the terms of the agreement, Mayne Pharma will pay milestones of at least 10 million euros ($10.59 million) following approval by US (FDA) . Mithra will produce Myring for Mayne Pharma in its Research, Development and Production Center (Mithra CDMO) .Under the terms of the agreement, Mithra will receive 2.4 million euros upon signing.  Full Article

Mayne Pharma Group HY revenue $294.8mln, up 132% on 1hfy16
Thursday, 23 Feb 2017 04:56pm EST 

Mayne Pharma Group Ltd - : Hy revenue of $294.8m, an increase of 132% on 1hfy16 .Hy reported net profit after tax of $72.7m, up 278%.  Full Article

Mayne Pharma says multiple US states commenced legal proceedings against Mayne
Thursday, 15 Dec 2016 07:39pm EST 

Mayne Pharma Group Ltd - : Multiple US states commenced legal proceedings in United States District Court Of Connecticut against number of US generic companies including Mayne . Board continues to believe investigations and legal proceedings will not have a material impact on its future earnings . US states allege co engaged in conduct in doxycycline hyclate delayed-release market with heritage pharmaceuticals that was anti- competitive .No assurance can be given as to timing or outcome of investigation or legal proceedings.  Full Article

Mayne Pharma says multiple US states commenced legal proceedings against Mayne
Thursday, 15 Dec 2016 06:47pm EST 

Mayne Pharma Group Ltd - : Multiple US states commenced legal proceedings in United States District Court Of Connecticut against number of US generic companies including Mayne . Board continues to believe investigations and legal proceedings will not have a material impact on its future earnings . US states allege co engaged in conduct in doxycycline hyclate delayed-release market with heritage pharmaceuticals that was anti- competitive .No assurance can be given as to timing or outcome of investigation or legal proceedings.  Full Article

H2-Pharma LLC says has acquired exclusive rights to distribute fifteen products from Mayne Pharma Inc
Tuesday, 6 Dec 2016 07:30am EST 

Mayne Pharma Group Ltd :H2-Pharma LLC says has acquired exclusive rights to distribute fifteen products from Mayne Pharma Inc.  Full Article

Mayne Pharma Group updates on legal proceedings
Thursday, 3 Nov 2016 07:49pm EDT 

Mayne Pharma Group Ltd : Continues to believe these investigations will not have a material impact on its future earnings . No assurance can be given as to timing or outcome of investigation . Disclosed that it was one of several generic companies to receive a subpoena from Antitrust Division Of Us Department Of Justice . Investigation relating to Mayne Pharma is focused on doxycycline hyclate delayed-release tablets and potassium chloride powders .Antitrust division of US department of justice seeking information relating to marketing, pricing and sales of select generic products.  Full Article

Mayne Pharma launches Budesonide capsules in United States
Wednesday, 26 Oct 2016 06:11pm EDT 

Mayne Pharma Group Ltd :Mayne Pharma launches budesonide capsules in us.  Full Article

Mayne Pharma Group says acquisition of US foam dermatology assets
Wednesday, 17 Aug 2016 07:26pm EDT 

Mayne Pharma Group Ltd : MYX announces acquisition of US foam dermatology assets . Says deal for a consideration for US$50.1 million . Has acquired a portfolio of on-market dermatology foam assets from GSK . Expects products to contribute modest incremental EBITDA in FY 2017 and have significant potential for growth in future years .  Full Article

Mayne Pharma updates on trading halt
Wednesday, 29 Jun 2016 06:47pm EDT 

Mayne Pharma Group Ltd : Expects trading halt to be lifted and ordinary shares to recommence trading on an ex-entitlement basis from market open today .  Full Article

More From Around the Web